Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 15.250-16.250 for the period, compared to the consensus estimate of 16.240. The company issued revenue guidance of -.

Analysts Set New Price Targets

BIIB has been the topic of several recent research reports. Canaccord Genuity Group cut their target price on shares of Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday. Piper Sandler downgraded shares of Biogen from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $315.00 to $138.00 in a research report on Thursday, January 2nd. Oppenheimer lowered their target price on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Citigroup reduced their price objective on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Bank Of America (Bofa) decreased their price target on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research note on Tuesday. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $211.96.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $140.83 on Friday. The stock’s fifty day simple moving average is $147.31 and its 200 day simple moving average is $173.80. Biogen has a 52-week low of $128.51 and a 52-week high of $238.00. The stock has a market capitalization of $20.52 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 1.65 and a beta of -0.08. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%. As a group, sell-side analysts forecast that Biogen will post 16.42 earnings per share for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.